Lowers the risk of myocardial infarction, myocardial revascularization procedures, and…. ANDA 77917, held by Chartwell Rx. Pravastatin Sodium.
As of Nov 16, 2026, ANDA 77917 (Pravastatin Sodium), held by Chartwell Rx, was first approved by FDA on Jan 8, 2008, with 7 approved supplements and 0 published complete response letters.
Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated lowdensity lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 8, 2008 | Original application | Approved | None posted |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Rx |
| Mar 17, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Oct 13, 2022 | Supplement 21Labeling · Standard review | Approved | None posted |
| Feb 1, 2021 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jul 11, 2017 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 3, 2014 | Supplement 16Manufacturing | Approved | None posted |
| Apr 18, 2013 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jun 16, 2008 | Supplement 2Labeling | Approved | None posted |
| Jan 8, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters